Concerns Over Vaccine Scheduling and Myocarditis Risks

This chapter explores the internal discussions within the CDC regarding COVID-19 vaccine dosing for young children during spring 2021. It examines the potential actions the agency could have implemented to address myocarditis risks and contrasts these with decisions made in Europe, culminating in the resignations of FDA vaccine officials.